Skip to main content

Advertisement

Table 2 Treatment factors associated with reduced P. aeruginosa bacterial burden at END of PEx therapies

From: Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response

Factor ALL MUC NON
Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI)
1-log reduction 2-log reduction 1-log reduction 2-log reduction 1-log reduction 2-log reduction
Antibiotics*
FEP vs other ABx 7/22 vs 61/97 0.51 (0.27-0.95), p = 0.009 6/22 vs 49/97 0.54 (0.26-1.08), p = 0.06 13/20 vs 61/81 0.86 (0.61-1.22), p = 0.40 7/20 vs 49/81 0.57 (0.31-1.00), p = 0.05 9/21 vs 55/89 0.69 (0.41-1.16), p = 0.14 6/21 vs 45/89 0.56 (0.28-1.14), p = 0.08
CAZ vs other ABx 36/56 vs 32/63 1.27 (0.93-1.73), p = 0.19 29/56 vs 26/63 1.25 (0.85-1.85), p = 0.27 36/49 vs 38/52 1.00 (0.8-1.27), p = 1.0 32/49 vs 24/52 1.41 (0.99-2.02), p = 0.08 34/50 vs 30/60, 1.36 (0.99-1.86), p = 0.07 27/50 vs 24/60 1.35 (0.90-2.01, p = 0.18
Treatment parameters*
<14 vs ≥14 days 32/68 vs 29/52 0.84 (0.6-1.2), p = 0.36 23/55 vs 38/65 0.7 (0.5-1.24), p = 0.09 38/74 vs 13/28 1.1 (0.7-1.74), p = 0.8 25/56 vs 26/46 0.78 (0.53-1.16),p = 0.3 30/64 vs 28/46 0.77 (0.54-1.1), p = 0.17 20/51 vs 38/59 0.6 (0.41-0.9), p = 0.01
  1. *Other antibiotics including aztreonam, meropenem, ciprofloxacin and dosing of tobramycin did not show significance and have not been included.
  2. CAZ = Ceftazidime, FEP = Cefepime, ABx = antibiotics.